IMBiologics Corp

Company Profile

• Business description

  IMBiologics Corp is a clinical-stage biopharmaceutical company focused on developing differentiated biologic therapies for immunology and inflammation (I&I) and cancer. The company advances next-generation therapeutics using novel target biology, Modern antibody engineering, and proprietary multivalent platform technologies. It is committed to delivering impactful therapies to patients while creating long-term value through scientific innovation and world-wide collaboration. The group's proprietary IM-OpDECon platform enables the development of novel antibody-based therapeutics with differentiated mechanisms of action. It is advancing a portfolio of new programs, including IMB-101/102, IMB-106, IMB-201, and IMB-402, across autoimmune, inflammatory, and immuno-oncology indications.

• Contact

  260 Changnyong-daero
  11th Floor, Gwanggyo Central Biz Tower
  Yeongtong-gu, Iui-dong
  Gyeonggi-do
  Suwon-si
  KOR

  T: +82 3180678170

  https://www.imbiologics.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Biotechnology

  Fiscal Year End

  Employees